Cary G. Vance
President and Chief Executive Officer
Mr. Vance was appointed President and CEO of Titan Medical in July 2022. Prior to being appointed, he served as an independent director for Titan Medical’s Board of Directors and as the company’s Human Resources/Compensation Committee Chair leading the company’s compensation policies and philosophical direction.
Previously, he served as President and CEO at Xcath Incorporated and drove strategic and tactical initiatives to advance the robotic platform enabling precise manipulation of robotically steerable guidewires for neurovascular and peripheral vascular clinical applications. Prior to Xcath, Mr. Vance led OptiScan Biomedical Corporation as President and CEO, leveraging a novel medical technology platform that continuously monitored systems in the surgical intensive care unit.
Prior to this, Mr. Vance served as President and CEO at Myoscience Incorporated, and President and CEO of Hansen Medical Inc. While at
Hansen Medical, he strategically transformed the business and markets with disruptive, enabling and game-changing interventional robotic techniques and technology. Mr. Vance drove adoption and record levels of year-over-year catheter utilization and system placements, while significantly reducing and reallocating spending levels. He later executed on an equity and debt financing strategy as an integral step to a successful M&A event. Prior to Hansen, Mr. Vance served in various global executive leadership roles over 20 years at Teleflex, Covidien and GE Healthcare. Mr. Vance currently serves on the AdvaMed Accel Board of Directors and is NACD Directorship Certified and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University.
Chief Financial Officer
Mr. Lemieux has more than 18 years of experience in public companies including over 9 years as a Chief Financial Officer and 13 years in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at over $400 million. Mr. Lemieux served as CFO and Secretary of NeuPath Health (TSXV: NPTH) from 2019 to 2021.
Prior to NeuPath, Mr. Lemieux served as the CFO and Secretary at Cipher Pharmaceuticals (TSX:CPH) from 2016 to 2019 and acted as Interim-CEO from November 2016 to April 2017. Prior to Cipher Pharmaceuticals, Mr. Lemieux was CFO at Nuvo Pharmaceuticals (TSX:NRI) and Crescita Therapeutics (TSX:CTX). Crescita was created on March 1, 2016 by way of a plan of arrangement that reorganized Nuvo Research Inc. into Nuvo and Crescita. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.
Vice President, Legal, IP and Strategic Initiatives, General Counsel
Mr. Brar draws from more than 15 years of technical, business and legal experience to manage Titan’s legal affairs while leading and executing a comprehensive IP program that facilitates innovation, enhances business objectives and mitigates risks. Working alongside other Titan executives, engineering teams and advisers, Mr. Brar ensures that the company’s IP strategy remains in alignment with – and continues to influence and enhance – the company’s overall business strategy.
Before joining Titan, Mr. Brar practiced with the law firm of Smart & Biggar in Vancouver, British Columbia. Before practicing law, he worked as an engineer and in product marketing with National Semiconductor in Santa Clara, California. Mr. Brar is deeply passionate about innovation that enhances people’s quality of life and the role of intellectual property in driving, supporting and testing such innovation. He has a Law degree (LL.B.) and a Bachelor of Science degree in Computer Engineering, both from the University of Manitoba.
Vice President, Manufacturing and Operations
Mr. Fahey brings more than 20 years of product development, manufacturing and commercialization experience in the medical device industry. He has been responsible for creating and leading product development engineering teams and processes to meet regulatory requirements, execute on strategy and foster cross-functional efficiency and accountability.
Most recently, Mr. Fahey served as Senior Vice President of Engineering at Precision Spine/Spinal USA, a spinal implant company where he drove multiple product releases and line extensions that were manufactured in-house. Before joining Precision Spine, Bill spent over five years with Orthofix/Blackstone Medical Inc. as Sr. Director of Engineering. He also held a product development position in Stryker’s Spine division. Mr. Fahey holds a Bachelor of Science Degree in Mechanical Engineering from Villanova University.
Vice President, Finance
Mr. Huang is a financial executive with over 20 years of experience developing and implementing financial models and systems, and accounting practices to support the achievement of strategic corporate objectives.
Mr. Huang has strong expertise in evaluating investment opportunities and long-term value creation as well as extensive knowledge of IFRS and U.S. GAAP reporting requirements. Most recently, he served as Senior Vice President, Corporate Finance at Quarterhill Inc., where he led the finance systems migration and reorganized key business processes, streamlining external reporting processes. Prior to Quarterhill, Mr. Huang served as Vice President, Finance at Aralez Pharmaceuticals, responsible for implementing systems upgrades, negotiating potential divestitures and advising on private equity financing. Prior to this, Mr. Huang was Senior Director, Finance at Astellas Pharma. Mr. Huang holds a Bachelor of Science in Physiology from the University of Toronto, a Graduate Diploma in Public Accountancy from McGill University, and has Chartered Accountant Designation.
Director of Human Resources